JP2004536869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536869A5 JP2004536869A5 JP2003515522A JP2003515522A JP2004536869A5 JP 2004536869 A5 JP2004536869 A5 JP 2004536869A5 JP 2003515522 A JP2003515522 A JP 2003515522A JP 2003515522 A JP2003515522 A JP 2003515522A JP 2004536869 A5 JP2004536869 A5 JP 2004536869A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- aminocarbonyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 230000003287 optical effect Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- -1 cyano, hydroxyl Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- QRWXQTUTFBGJHU-UHFFFAOYSA-N 2-(carbamoylamino)-5-(1h-indol-3-yl)-4-methylthiophene-3-carboxamide Chemical compound S1C(NC(N)=O)=C(C(N)=O)C(C)=C1C1=CNC2=CC=CC=C12 QRWXQTUTFBGJHU-UHFFFAOYSA-N 0.000 claims 1
- DTGUWAQNQUYFQF-UHFFFAOYSA-N 2-(carbamoylamino)-5-(1h-indol-5-yl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=C3C=CNC3=CC=2)=C1 DTGUWAQNQUYFQF-UHFFFAOYSA-N 0.000 claims 1
- SWVARBRJKGYPIV-UHFFFAOYSA-N 2-(carbamoylamino)-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-methylthiophene-3-carboxamide Chemical compound S1C(NC(N)=O)=C(C(N)=O)C(C)=C1C1=CC=C(OCCO2)C2=C1 SWVARBRJKGYPIV-UHFFFAOYSA-N 0.000 claims 1
- HYLSCTUBXRDDOD-UHFFFAOYSA-N 2-(carbamoylamino)-5-[4-(2-morpholin-4-ylethoxy)-1-benzothiophen-2-yl]thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2SC3=CC=CC(OCCN4CCOCC4)=C3C=2)=C1 HYLSCTUBXRDDOD-UHFFFAOYSA-N 0.000 claims 1
- ACPLTAYZHQVNHA-UHFFFAOYSA-N 2-(carbamoylamino)-5-quinolin-3-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=C3C=CC=CC3=NC=2)=C1 ACPLTAYZHQVNHA-UHFFFAOYSA-N 0.000 claims 1
- JTXJRZUQPFHBOL-UHFFFAOYSA-N 2-(carbamoylamino)-5-quinolin-8-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C3=NC=CC=C3C=CC=2)=C1 JTXJRZUQPFHBOL-UHFFFAOYSA-N 0.000 claims 1
- LQMABRNIZVPJKS-UHFFFAOYSA-N 5-(1-benzofuran-2-yl)-2-(carbamoylamino)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2OC3=CC=CC=C3C=2)=C1 LQMABRNIZVPJKS-UHFFFAOYSA-N 0.000 claims 1
- IEMLTPOVTUCHJA-UHFFFAOYSA-N 5-(1-benzothiophen-2-yl)-2-(carbamoylamino)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2SC3=CC=CC=C3C=2)=C1 IEMLTPOVTUCHJA-UHFFFAOYSA-N 0.000 claims 1
- UPTJSTVOSJABLJ-UHFFFAOYSA-N 5-(1-benzothiophen-2-yl)-3-(carbamoylamino)thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC2=CC=CC=C2S1 UPTJSTVOSJABLJ-UHFFFAOYSA-N 0.000 claims 1
- LWXZDSSKXHVDRF-UHFFFAOYSA-N 5-(1-benzothiophen-3-yl)-2-(carbamoylamino)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C3=CC=CC=C3SC=2)=C1 LWXZDSSKXHVDRF-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 claims 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000000843 powder Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102617A SE0102617D0 (sv) | 2001-07-25 | 2001-07-25 | Novel compounds |
| PCT/SE2002/001402 WO2003010163A1 (en) | 2001-07-25 | 2002-07-19 | Novel compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009291103A Division JP2010111683A (ja) | 2001-07-25 | 2009-12-22 | 新規化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536869A JP2004536869A (ja) | 2004-12-09 |
| JP2004536869A5 true JP2004536869A5 (enExample) | 2009-09-03 |
Family
ID=20284945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003515522A Withdrawn JP2004536869A (ja) | 2001-07-25 | 2002-07-19 | 新規化合物 |
| JP2009291103A Pending JP2010111683A (ja) | 2001-07-25 | 2009-12-22 | 新規化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009291103A Pending JP2010111683A (ja) | 2001-07-25 | 2009-12-22 | 新規化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7098240B2 (enExample) |
| EP (1) | EP1421079B1 (enExample) |
| JP (2) | JP2004536869A (enExample) |
| KR (1) | KR20040018521A (enExample) |
| CN (1) | CN1538968A (enExample) |
| AT (1) | ATE353327T1 (enExample) |
| BR (1) | BR0211472A (enExample) |
| CA (1) | CA2454702A1 (enExample) |
| DE (1) | DE60218048T2 (enExample) |
| ES (1) | ES2280559T3 (enExample) |
| IL (1) | IL160023A0 (enExample) |
| MX (1) | MXPA04000755A (enExample) |
| NO (1) | NO20040314L (enExample) |
| NZ (1) | NZ530751A (enExample) |
| SE (1) | SE0102617D0 (enExample) |
| WO (1) | WO2003010163A1 (enExample) |
| ZA (1) | ZA200400494B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| PT1401825E (pt) * | 2001-06-11 | 2009-10-23 | Virochem Pharma Inc | Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus |
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| ES2315430T3 (es) * | 2001-10-04 | 2009-04-01 | Smithkline Beecham Corporation | Inhibidores de nf-kb. |
| US7375131B2 (en) * | 2002-06-06 | 2008-05-20 | Smithklinebeecham Corp. | NF-κB inhibitors |
| CN100413861C (zh) | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
| SE0300091D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| SE0300092D0 (sv) | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
| EP1631560A2 (en) * | 2003-04-25 | 2006-03-08 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
| US20050113566A1 (en) * | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
| US7427683B2 (en) * | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
| EP1493739A1 (fr) * | 2003-07-03 | 2005-01-05 | Warner-Lambert Company LLC | Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| RU2397168C2 (ru) * | 2004-01-05 | 2010-08-20 | Астразенека Аб | Производные тиофена в качестве ингибиторов снк 1 |
| PE20060373A1 (es) | 2004-06-24 | 2006-04-29 | Smithkline Beecham Corp | Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2 |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| NZ563909A (en) | 2005-05-13 | 2011-10-28 | Virochem Pharma Inc | Thiophene derivatives and their use for the treatment or prevention of flavivirus infections |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| MX2007016541A (es) | 2005-06-30 | 2008-03-07 | Smithkline Beecham Corp | Compuestos quimicos. |
| CA2670260A1 (en) | 2006-11-15 | 2008-05-22 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of flavivirus infections |
| KR20090109551A (ko) * | 2007-01-15 | 2009-10-20 | 산텐 세이야꾸 가부시키가이샤 | ＩκＢ 키나아제 β 저해 활성을 갖는 신규 인돌 유도체 |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| KR20210107137A (ko) | 2008-04-21 | 2021-08-31 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| CN102089281A (zh) * | 2008-07-14 | 2011-06-08 | 参天制药株式会社 | 具有氨基甲酰基、脲基及取代氧基的新型吲哚衍生物 |
| US8088817B2 (en) * | 2008-08-25 | 2012-01-03 | Santen Pharmaceutical Co., Ltd. | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| EP2520292A1 (en) | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders |
| US10821185B2 (en) | 2016-06-29 | 2020-11-03 | Otonomy Inc. | Triglyceride otic formulations and uses thereof |
| CN107739370B (zh) * | 2017-10-26 | 2021-03-30 | 中国药科大学 | 吡咯酮类brd4蛋白抑制剂的制备方法以及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1468012A (en) | 1973-08-09 | 1977-03-23 | Beecham Group Ltd | 2-amino-3-carboxy-thiophene derivatives |
| DE3529247A1 (de) | 1985-05-17 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung |
| AU3044197A (en) | 1996-07-11 | 1998-02-09 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
| PT853083E (pt) * | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| US6809088B2 (en) * | 1997-03-24 | 2004-10-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| US6037340A (en) | 1997-05-28 | 2000-03-14 | Cadus Pharmaceutical Corporation | Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| AU2713799A (en) | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| HN2000000051A (es) * | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| HUP0300382A3 (en) * | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| JP2004523476A (ja) | 2000-10-12 | 2004-08-05 | スミスクライン・ビーチャム・コーポレイション | ＮＦ−κＢ阻害剤 |
-
2001
- 2001-07-25 SE SE0102617A patent/SE0102617D0/xx unknown
-
2002
- 2002-07-19 EP EP02756047A patent/EP1421079B1/en not_active Expired - Lifetime
- 2002-07-19 AT AT02756047T patent/ATE353327T1/de not_active IP Right Cessation
- 2002-07-19 NZ NZ530751A patent/NZ530751A/en unknown
- 2002-07-19 JP JP2003515522A patent/JP2004536869A/ja not_active Withdrawn
- 2002-07-19 US US10/484,645 patent/US7098240B2/en not_active Expired - Fee Related
- 2002-07-19 MX MXPA04000755A patent/MXPA04000755A/es unknown
- 2002-07-19 KR KR10-2004-7001155A patent/KR20040018521A/ko not_active Withdrawn
- 2002-07-19 IL IL16002302A patent/IL160023A0/xx unknown
- 2002-07-19 CA CA002454702A patent/CA2454702A1/en not_active Abandoned
- 2002-07-19 BR BR0211472-0A patent/BR0211472A/pt not_active IP Right Cessation
- 2002-07-19 CN CNA028152514A patent/CN1538968A/zh active Pending
- 2002-07-19 DE DE60218048T patent/DE60218048T2/de not_active Expired - Lifetime
- 2002-07-19 WO PCT/SE2002/001402 patent/WO2003010163A1/en not_active Ceased
- 2002-07-19 ES ES02756047T patent/ES2280559T3/es not_active Expired - Lifetime
-
2004
- 2004-01-22 ZA ZA200400494A patent/ZA200400494B/en unknown
- 2004-01-23 NO NO20040314A patent/NO20040314L/no unknown
-
2009
- 2009-12-22 JP JP2009291103A patent/JP2010111683A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536869A5 (enExample) | ||
| JP2007512299A5 (enExample) | ||
| KR100900304B1 (ko) | 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체 | |
| JP2002536445A5 (enExample) | ||
| JP2005535586A5 (enExample) | ||
| JP2003503385A5 (enExample) | ||
| JP2001526269A5 (enExample) | ||
| JP2014526501A5 (enExample) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2009520685A5 (enExample) | ||
| JP2005538100A5 (enExample) | ||
| ES2380704T9 (es) | Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico | |
| WO2000047194A9 (en) | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | |
| JP2008524246A5 (enExample) | ||
| JP2006528685A5 (enExample) | ||
| RU2015121043A (ru) | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 | |
| JP2020516671A5 (enExample) | ||
| JP2009543843A (ja) | 直接トロンビン阻害剤に関する新規適応 | |
| JP2020512337A5 (enExample) | ||
| JP2006511552A5 (enExample) | ||
| JP2009511513A5 (enExample) | ||
| CA2819997C (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| JP2006510606A5 (enExample) | ||
| RU2009113602A (ru) | Изосериновые производные для применения в качестве ингибиторов фактора свертывания крови ixa | |
| JP2003513075A5 (enExample) |